The frequency of carpal tunnel syndrome (CTS) is increased in patients with peripheral neuropathy from a variety of causes (1). Abnormal glucose metabolism may be implicated in the etiology of “idiopathic” polyneuropathy in subjects who do not have diabetes (2). We investigated whether the incidence of CTS, Bell’s palsy, and other peripheral nerve disorders is increased before the diagnosis of diabetes.

A cohort study was implemented (3) using THIN, a database containing medical records from family practices in England and Wales (4). The study was approved by the South East Research Ethics Committee. Data were analyzed for 114 family practices with 644,495 registered patients aged ≤100 years. Diabetes cases were selected if their diagnosis date was between 1 November 2003 and 31 October 2004 and if they were aged between 30 and 89 years at diagnosis and had never been prescribed insulin or diagnosed with type 1 diabetes. These criteria produced 2,655 cases. Two control groups were randomly selected, matching for age, sex, and practice, from subjects who were never diagnosed with diabetes or prescribed oral hypoglycemic drugs or insulin. Eight cases, for whom two respective control subjects could not be identified, were omitted.

Each patient’s medical record was searched for first occurrences of CTS, including carpal tunnel release and carpal tunnel injection (5). We also identified new occurrences of Bell’s facial palsy. Other peripheral neuropathies were grouped, including mononeuritis of the upper limb excluding CTS, mononeuritis of the lower limb, mononeuritis multiplex, and peripheral neuropathy (including idiopathic progressive polyneuropathy, polyneuropathy, peripheral neuropathy, other idiopathic peripheral neuropathy, hereditary or idiopathic peripheral neuropathy not otherwise specific, and inflammatory and toxic neuropathies) (5).

The entry date to the study was the earlier of the start of the Windows-based medical record or the date of the first prescription following registration (up to a maximum of 10 years before the diabetes diagnosis date). There were 82 subjects who were diagnosed with CTS, 23 with Bell’s palsy, and 28 with other peripheral nervous disorders before the entry date to the study, and these subjects were omitted. The interpretation did not differ if analyses were restricted to the Windows-based record only, but this resulted in exclusion of an additional 45 cases of CTS and 7 of Bell’s palsy. Proportional hazards models were fitted to estimate the relative risk of each neuropathy in pre-diabetic subjects compared with control subjects. Analyses were adjusted for known risk factors for CTS (6), including BMI category (<25, 25.0–29.9, and ≥30 kg/m2 and not known) and whether the subject ever had a diagnosis of thyroid disease, rheumatoid arthritis, osteoarthritis, or previous wrist fracture before the diagnosis of CTS. Robust SEs were estimated according to the identifier for each triplet, of one case and two control subjects, which was unique across all practices. There was no evidence from any analysis that the proportional hazards assumption was invalid.

There were 2,647 subjects with pre-diabetes who were later diagnosed with diabetes in 2003–2004 and 5,294 control subjects matched for age, sex, and practice. The mean (±SD) age was 62.4 ± 13.1 years, and 49% were women. The mean duration of follow-up contributed by each subject was 8.9 ± 1.7 years for pre-diabetic cases and 8.8 ± 1.7 years for control subjects. The incidence of CTS was 425.1 per 100,000 person-years in pre-diabetic and 260.0 per 100,000 in control subjects (Table 1). The relative risk was 1.63 (95% CI 1.26–2.11, P < 0.001). After adjusting for known risk factors for CTS, the relative risk was 1.36 (1.02–1.81, P = 0.039). The incidence of Bell’s palsy in pre-diabetic subjects was nearly twice that for control subjects. This increased risk of Bell’s palsy in pre-diabetic subjects was not independent of elevated BMI, which is itself a cause of pre-diabetes (Table 1). There were 85 incident cases of other peripheral nerve disorders, including 29 in pre-diabetic and 56 in control subjects. The relative risk was 1.02 (0.65–1.58, P = 0.939). However, there were only 20 cases of “peripheral neuropathy” (7 in pre-diabetic and 13 in control subjects) and no recorded cases of “idiopathic progressive polyneuropathy.”

The present study had the strengths of a large sample size and a long duration of prospective data collection. Nevertheless, because of the relative rarity of these conditions, we have studied small numbers of cases and our estimates are imprecise. The main limitations are those of the clinical methods used for case definition and case ascertainment. We have used the term “pre-diabetes” to refer to the time before the diagnosis of diabetes. During this time, individual subjects may have normal glucose tolerance or varying degrees of hyperglycemia, including impaired fasting glucose, impaired glucose tolerance, or undiagnosed diabetes (7). The increased incidence of CTS in pre-diabetic subjects is comparable with the results of studies that have identified type 2 diabetes as a risk factor for CTS (6). However, previous studies generally included cases with diabetes of long duration. The present study makes the novel observation that the incidence of CTS is increased from before the time of clinical diagnosis of diabetes when exposure to hyperglycemia will generally have been less prolonged and less severe.

Additional analyses showed that corticosteroids were prescribed to a minority of patients following diagnosis of CTS or Bell’s palsy with little difference in frequency between pre-diabetic cases and control subjects. The use of steroids for these indications is unlikely to have been of sufficient duration or dosage to cause diabetes. Adjustment for other risk factors for CTS, including obesity or history of arthritis, wrist fracture, and thyroid disease, partially accounted for the increased risk of CTS in pre-diabetic subjects. Missing and misclassified values were likely to lead to incomplete adjustment. However, while obesity is associated with increased risk of CTS (8,9), obesity is also a cause of hyperglycemia and is not a true confounder. Nondiabetic hyperglycemia may be associated with peripheral nerve dysfunction (2,10,11). The present results show an increase in two common peripheral nerve disorders, CTS and Bell’s palsy, which are easily recognized in primary care. Hyperglycemia and associated metabolic abnormalities may contribute to causing these important focal peripheral nerve disorders before the diagnosis of diabetes.

Table 1—

Incidence of CTS, Bell’s facial palsy, and other peripheral nerve disorders during study period up to 10 years before diabetes diagnosis

nPerson-yearsEvents (no.)Incidence rate (per 100,000 person-years)Relative risk (95% CI)P valueAdjusted relative risk (95% CI)P value
CTS         
    Pre-diabetic subjects 2,613 22,820 97 425.1 1.63 (1.26–2.11) <0.001 1.36 (1.02–1.81)* 0.039 
    Control subjects 5,246 45,393 118 260.0     
Bell’s facial palsy         
    Pre-diabetic subjects 2,636 23,425 19 81.1 1.96 (1.04–3.70) 0.039 1.64 (0.87–3.11) 0.128 
    Control subjects 5,282 46,163 19 41.2     
Other peripheral nerve disorders         
    Pre-diabetic subjects 2,632 23,296 29 124.5 1.02 (0.65–1.58) 0.939 0.96 (0.60–1.52) 0.857 
    Control subjects 5,281 46,038 56 121.6     
nPerson-yearsEvents (no.)Incidence rate (per 100,000 person-years)Relative risk (95% CI)P valueAdjusted relative risk (95% CI)P value
CTS         
    Pre-diabetic subjects 2,613 22,820 97 425.1 1.63 (1.26–2.11) <0.001 1.36 (1.02–1.81)* 0.039 
    Control subjects 5,246 45,393 118 260.0     
Bell’s facial palsy         
    Pre-diabetic subjects 2,636 23,425 19 81.1 1.96 (1.04–3.70) 0.039 1.64 (0.87–3.11) 0.128 
    Control subjects 5,282 46,163 19 41.2     
Other peripheral nerve disorders         
    Pre-diabetic subjects 2,632 23,296 29 124.5 1.02 (0.65–1.58) 0.939 0.96 (0.60–1.52) 0.857 
    Control subjects 5,281 46,038 56 121.6     

Results after omitting 82 prevalent cases of CTS, 23 prevalent cases of Bell’s palsy, or 28 prevalent cases of “other peripheral nervous system disorders.”

*

Adjusted for sex, age-group, BMI category, and whether subject had history of thyroid disorders, wrist fractures, rheumatoid arthritis, and osteoarthritis before CTS diagnosis.

Adjusted for sex, age-group, and BMI category only.

The authors thank the staff of EPIC, U.K., for facilitating use of the THIN database.

1.
Stevens JC: Median neuropathy. In
Peripheral Neuropathy
. Dyck PJ, Thomas PK, Eds. Philadelphia, Elsevier Saunders,
2005
, p.
1435
–1461
2.
Novella SP, Inzucchi SE, Goldstein JM: The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy.
Muscle Nerve
24
:
1229
–1231,
2001
3.
Gulliford MC, Charlton J, Latinovic R: Increased utilization of primary care 5 years before diagnosis if type 2 diabetes: a matched cohort study.
Diabetes Care
28
:
47
–52,
2005
4.
Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, Farrington P, Britton J: Bupropion and the risk of sudden death: a self-controlled case-series analysis using the Health Improvement Network.
Thorax
60
:
848
–850,
2005
5.
National Health Service Connecting for Health:
Clinical Terms (Read Codes)
. Birmingham, U.K., National Health Service Information Authority,
2004
6.
Geoghegan JM, Clark DI, Bainbridge LC, Smith C, Hubbard R: Risk factors in carpal tunnel syndrome.
J Hand Surg
29
:
315
–320,
2004
7.
Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis.
Diabetes Care
15
:
815
–819,
1992
8.
Becker J, Nora DB, Gomes I, Stringari FF, Seitensus R, Panosso JS, Ehlers JA: An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome.
Clin Neurophysiol
113
:
1429
–1434,
2002
9.
Bland JD: The relationship of obesity, age, and carpal tunnel syndrome: more complex than was thought?
Muscle Nerve
32
:
527
–532,
2005
10.
Singleton JR, Smith AG, Bromberg MB: Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.
Diabetes Care
24
:
1448
–1453,
2001
11.
Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M: The spectrum of neuropathy in diabetes and impaired glucose tolerance.
Neurology
60
:
108
–111,
2003

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.